{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:57:57Z","timestamp":1784059077767,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"BioTheryX"},{"name":"National Cancer Institute","award":["R01s CA184464 and CA194264"],"award-info":[{"award-number":["R01s CA184464 and CA194264"]}]},{"name":"Leukemia & Lymphoma Society Specialized Center of Research","award":["SCOR-12206-17"],"award-info":[{"award-number":["SCOR-12206-17"]}]},{"name":"Dr. Mirian and Sheldon G. Adelson Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00109-020-01943-6","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T20:03:33Z","timestamp":1594065813000},"page":"1161-1173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance"],"prefix":"10.1007","volume":"98","author":[{"given":"Jianxuan","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isere","family":"Kuiatse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazal","family":"Shirazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet E.","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Erdman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"McElwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparajita H.","family":"Chourasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle W. H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Stirling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4129","authenticated-orcid":false,"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"issue":"5","key":"1943_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, McCarthy PL (2017) Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs 77(5):505\u2013520","journal-title":"Drugs"},{"issue":"1","key":"1943_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/PPO.0000000000000349","volume":"25","author":"G Bianchi","year":"2019","unstructured":"Bianchi G, Anderson KC (2019) Contribution of inhibition of protein catabolism in myeloma. Cancer J 25(1):11\u201318","journal-title":"Cancer J"},{"issue":"5971","key":"1943_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science 327(5971):1345\u20131350","journal-title":"Science"},{"issue":"2","key":"1943_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11033-007-9077-3","volume":"35","author":"W Xin","year":"2008","unstructured":"Xin W, Xiaohua N, Peilin C, Xin C, Yaqiong S, Qihan W (2008) Primary function analysis of human mental retardation related gene CRBN. Mol Biol Rep 35(2):251\u2013256","journal-title":"Mol Biol Rep"},{"issue":"6","key":"1943_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.molcel.2007.06.001","volume":"26","author":"J Lee","year":"2007","unstructured":"Lee J, Zhou P (2007) DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell 26(6):775\u2013780","journal-title":"Mol Cell"},{"key":"1943_CR6","doi-asserted-by":"crossref","unstructured":"Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, et al. (2014) Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 124(4):536\u2013545","DOI":"10.1182\/blood-2014-02-557819"},{"issue":"6168","key":"1943_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X et al (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343(6168):301\u2013305","journal-title":"Science"},{"issue":"6168","key":"1943_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343(6168):305\u2013309","journal-title":"Science"},{"issue":"9","key":"1943_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/ni.1915","volume":"11","author":"R Gandhi","year":"2010","unstructured":"Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ (2010) Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11(9):846\u2013853","journal-title":"Nat Immunol"},{"issue":"8","key":"1943_CR10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/ni.2363","volume":"13","author":"FJ Quintana","year":"2012","unstructured":"Quintana FJ, Jin H, Burns EJ, Nadeau M, Yeste A, Kumar D, Rangachari M, Zhu C, Xiao S, Seavitt J et al (2012) Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol 13(8):770\u2013777","journal-title":"Nat Immunol"},{"issue":"2","key":"1943_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1084\/jem.20031571","volume":"199","author":"M Cort\u00e9s","year":"2004","unstructured":"Cort\u00e9s M, Georgopoulos K (2004) Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity. J Exp Med 199(2):209\u2013219","journal-title":"J Exp Med"},{"issue":"2","key":"1943_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","volume":"61","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela ME, Zhang W, Man HW, Muller G, Khambatta G, Baculi F, Hickman M, LeBrun L, Pagarigan B, Carmel G et al (2018) A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem 61(2):535\u2013542","journal-title":"J Med Chem"},{"issue":"2","key":"1943_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1021\/acs.jmedchem.6b01911","volume":"61","author":"JD Hansen","year":"2018","unstructured":"Hansen JD, Condroski K, Correa M, Muller G, Man HW, Ruchelman A, Zhang W, Vocanson F, Crea T, Liu W et al (2018) Protein degradation via CRL4(CRBN) ubiquitin ligase: discovery and structure-activity relationships of novel glutarimide analogs that promote degradation of Aiolos and\/or GSPT1. J Med Chem 61(2):492\u2013503","journal-title":"J Med Chem"},{"issue":"7611","key":"1943_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu CC, Miller K, Fang W, Wang NY, Nguyen D, Houston J et al (2016) A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535(7611):252\u2013257","journal-title":"Nature"},{"issue":"12","key":"1943_CR15","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1002\/j.1460-2075.1989.tb08558.x","volume":"8","author":"S Hoshino","year":"1989","unstructured":"Hoshino S, Miyazawa H, Enomoto T, Hanaoka F, Kikuchi Y, Kikuchi A, Ui M (1989) A human homologue of the yeast GST1 gene codes for a GTP-binding protein and is expressed in a proliferation-dependent manner in mammalian cells. EMBO J 8(12):3807\u20133814","journal-title":"EMBO J"},{"issue":"4","key":"1943_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molcel.2013.12.028","volume":"53","author":"T Feng","year":"2014","unstructured":"Feng T, Yamamoto A, Wilkins SE, Sokolova E, Yates LA, M\u00fcnzel M, Singh P, Hopkinson RJ, Fischer R, Cockman ME et al (2014) Optimal translational termination requires C4 lysyl hydroxylation of eRF1. Mol Cell 53(4):645\u2013654","journal-title":"Mol Cell"},{"issue":"22","key":"1943_CR17","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-16-0861","volume":"22","author":"RZ Orlowski","year":"2016","unstructured":"Orlowski RZ, Lonial S (2016) Integration of novel agents into the care of patients with multiple myeloma. Clin Cancer Res 22(22):5443\u20135452","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1943_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32(2):252\u2013262","journal-title":"Leukemia"},{"key":"1943_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-med-112017-091045","volume":"70","author":"C Kunacheewa","year":"2019","unstructured":"Kunacheewa C, Orlowski RZ (2019) New drugs in multiple myeloma. Annu Rev Med 70:521\u2013547","journal-title":"Annu Rev Med"},{"issue":"9","key":"1943_CR20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kortum","year":"2016","unstructured":"Kortum KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L et al (2016) Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 128(9):1226\u20131233","journal-title":"Blood"},{"issue":"10","key":"1943_CR21","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1055-9965.EPI-10-0565","volume":"19","author":"W Ma","year":"2010","unstructured":"Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW et al (2010) Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomark Prev 19(10):2445\u20132452","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"13","key":"1943_CR22","doi-asserted-by":"publisher","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","volume":"286","author":"CC Bjorklund","year":"2011","unstructured":"Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ (2011) Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286(13):11009\u201311020","journal-title":"J Biol Chem"},{"issue":"2","key":"1943_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/leu.2013.174","volume":"28","author":"CC Bjorklund","year":"2014","unstructured":"Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M et al (2014) Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373\u2013383","journal-title":"Leukemia"},{"issue":"10","key":"1943_CR24","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41375-018-0044-x","volume":"32","author":"X Zhang","year":"2018","unstructured":"Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK et al (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32(10):2224\u20132239","journal-title":"Leukemia"},{"issue":"1","key":"1943_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjh.14525","volume":"177","author":"HC Lee","year":"2017","unstructured":"Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, Kuiatse I, Gu D, Wang Z, Ma W et al (2017) RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma. Br J Haematol 177(1):80\u201394","journal-title":"Br J Haematol"},{"issue":"2","key":"1943_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/emboj\/cdg017","volume":"22","author":"L Kisselev","year":"2003","unstructured":"Kisselev L, Ehrenberg M, Frolova L (2003) Termination of translation: interplay of mRNA, rRNAs and release factors? EMBO J 22(2):175\u2013182","journal-title":"EMBO J"},{"issue":"3","key":"1943_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","volume":"154","author":"A Lopez-Girona","year":"2011","unstructured":"Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A et al (2011) Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 154(3):325\u2013336","journal-title":"Br J Haematol"},{"issue":"14","key":"1943_CR28","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/onc.2015.245","volume":"35","author":"R Gopalakrishnan","year":"2016","unstructured":"Gopalakrishnan R, Matta H, Tolani B, Triche T Jr, Chaudhary PM (2016) Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35(14):1797\u20131810","journal-title":"Oncogene"},{"issue":"8","key":"1943_CR29","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2014.70","volume":"28","author":"M Affer","year":"2014","unstructured":"Affer M, Chesi M, Chen WG, Keats JJ, Demchenko YN, Roschke AV et al (2014) Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28(8):1725\u20131735","journal-title":"Leukemia"},{"issue":"1","key":"1943_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","volume":"34","author":"K Misund","year":"2019","unstructured":"Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, van Wier S, Riggs DL, Ahmann G, Chesi M et al (2019) MYC dysregulation in the progression of multiple myeloma. Leukemia 34(1):322\u2013326","journal-title":"Leukemia"},{"issue":"6","key":"1943_CR31","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3324\/haematol.2018.201483","volume":"104","author":"SL Lim","year":"2019","unstructured":"Lim SL, Damnernsawad A, Shyamsunder P, Chng WJ, Han BC, Xu L, Pan J, Pravin DP, Alkan S, Tyner JW et al (2019) Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. Haematologica 104(6):1209\u20131220","journal-title":"Haematologica"},{"issue":"3","key":"1943_CR32","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3109\/10428194.2014.924116","volume":"56","author":"IC Glitza","year":"2015","unstructured":"Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH (2015) Chromosome 8q24.1\/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56(3):602\u2013607","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1943_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bbrc.2019.10.119","volume":"521","author":"D Ichikawa","year":"2020","unstructured":"Ichikawa D, Nakamura M, Murota W, Osawa S, Matsushita M, Yanagawa H, Hattori Y (2020) A phenylphthalimide derivative, TC11, induces apoptosis by degrading MCL1 in multiple myeloma cells. Biochem Biophys Res Commun 521(1):252\u2013258","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1943_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tibs.2016.12.001","volume":"42","author":"M Kapanidou","year":"2017","unstructured":"Kapanidou M, Curtis NL, Bolanos-Garcia VM (2017) Cdc20: at the crossroads between chromosome segregation and mitotic exit. Trends Biochem Sci 42(3):193\u2013205","journal-title":"Trends Biochem Sci"},{"issue":"14","key":"1943_CR35","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","volume":"128","author":"JN Gong","year":"2016","unstructured":"Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, Khaw SL, Lessene G, Spencer A, Herold MJ et al (2016) Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood 128(14):1834\u20131844","journal-title":"Blood"},{"issue":"7626","key":"1943_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G et al (2016) The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538(7626):477\u2013482","journal-title":"Nature"},{"issue":"1","key":"1943_CR37","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD et al (2018) Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun 9(1):5341","journal-title":"Nat Commun"},{"issue":"12","key":"1943_CR38","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1101\/gad.215855.113","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, Opferman JT (2013) Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev 27(12):1351\u20131364","journal-title":"Genes Dev"},{"issue":"12","key":"1943_CR39","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1101\/gad.215871.113","volume":"27","author":"RL Thomas","year":"2013","unstructured":"Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, Fischer KM, Sussman MA, Miyamoto S, Gustafsson AB (2013) Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 27(12):1365\u20131377","journal-title":"Genes Dev"},{"issue":"11","key":"1943_CR40","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.4161\/auto.26168","volume":"9","author":"RL Thomas","year":"2013","unstructured":"Thomas RL, Gustafsson AB (2013) MCL1 is critical for mitochondrial function and autophagy in the heart. Autophagy 9(11):1902\u20131903","journal-title":"Autophagy"},{"issue":"14","key":"1943_CR41","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink EC, McConkey M, Adams DN, Haldar SD, Kennedy JA, Guirguis AA, Udeshi ND, Mani DR, Chen M, Liddicoat B et al (2018) Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132(14):1535\u20131544","journal-title":"Blood"},{"issue":"46","key":"1943_CR42","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1073\/pnas.1814446115","volume":"115","author":"Y Gemechu","year":"2018","unstructured":"Gemechu Y, Millrine D, Hashimoto S, Prakash J, Sanchenkova K, Metwally H, Gyanu P, Kang S, Kishimoto T (2018) Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proc Natl Acad Sci U S A 115(46):11802\u201311807","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-01943-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-020-01943-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-01943-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:03:02Z","timestamp":1650535382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-020-01943-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s00109-020-01943-6","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RS, LF, NR, PE, ET, IL, BM, AHC, KWHC, FM, and DIS are employees of BioTheryX, Inc., while the other authors have no financial conflicts of interest to declare with respect to BioTheryX, Inc.EEM has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, and Merck, and consultant fees from Takeda, Celgene, Sanofi, Janssen, GSK, and Adaptive Biotechnologies. HCL has provided consultancy services to Amgen, Inc., Celgene, a wholly owned subsidiary of Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical, Sanofi-Aventis, and Takeda Pharmaceutical, and has received research funding from Amgen, Inc., Celgene, a wholly owned subsidiary of Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceutical, and Takeda Pharmaceuticals. RZO declares laboratory research funding from BioTheryX, and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc. Also, RZO has served on advisory boards for Amgen, Inc., Bristol-Myers Squibb, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis, Servier, and Takeda Pharmaceuticals North America, Inc., and is a Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, though this technology does not bear on the current manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}